Amniotics AB (publ) (STO:AMNI)
Sweden · Delayed Price · Currency is SEK 0.0054
+0.0003 (5.88%)
Inactive · Last trade price on Sep 27, 2024
Amniotics AB Company Description
Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases.
The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease.
It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications.
The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals.
Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Amniotics AB (publ)
| Country | Sweden |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Marcus Larsson |
Contact Details
Address: ScheelevAegen 2 Lund | |
| Phone | 46 0 72 32 78 520 |
Stock Details
| Ticker Symbol | AMNI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015961016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marcus Larsson Ph.D. | Founding Member, Chief Executive Officer and Director |
| Gerton Jonsson | Chief Financial Officer |
| Jan Talts | Chief Operating Officer |
| Sidonie Karlsson | Head of Manufacturing |